// App-Quantinova.ai

: Efficacy of Mogamulizumab By Prior Systemic Therapy in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis from the Phase 3 Mavoric Study

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Steven M. Horwitz

  • Youn H. Kim

  • Alison J. Moskowitz

  • Pierluigi Porcu

  • Julia Scarisbrick

  • Mollie Leoni

  • Karen Dwyer

  • Wei Sun

  • Elena Nikonova

  • Martine Bagot

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Stanford Univeresity Medical Center, Stanford, CA

  • Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

  • University of Birmingham, Birmingham, United Kingdom

  • Kyowa Kirin Pharmaceutical Development, Inc., Princeton, NJ

  • Kyowa Kirin, Inc., Bedminster, NJ

  • Hopital Saint-Louis, AP-HP, Universite Paris , Paris, France

Locations

  • Italy

  • United States

  • United Kingdom

  • France

Companies

  • Kyowa Kirin Pharmace

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cutaneous T-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Mogamulizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01728805

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved